AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves

AHA 2020: RIVER Shows Rivaroxaban Safe for Patients with Bioprosthetic Valves

Results from the RIVER trial reveal important new information for the treatment of atrial fibrillation in patients with bioprosthetic mitral valves.

Read the Original Article>>

Source: Duke Clinical Research Institute

Send this to a friend